<DOC>
	<DOCNO>NCT02325713</DOCNO>
	<brief_summary>This phase I , open-label , randomize , 4 period , crossover , single-center trial . The purpose trial assess relative bio-availability racemate Oral Dispersible Tablet praziquantel ( ODT-PQZ ) ( MSC1028703A ) 150 milligram ( mg ) versus current market praziquantel ( PZQ ) ( CysticideÂ® 500 mg ) formulation healthy male volunteer .</brief_summary>
	<brief_title>Relative Bioavailability Trial Oral Dispersible Praziquantel Tablets Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Healthy male 1855 year age ( inclusive screening ) Male subject partner childbearing potential must vasectomy use acceptable method birth control ( , condom ) donate sperm , 90 day last dose trial medication Provide write informed consent prior trial related procedure Body weight great equal ( &gt; = ) 55.0 kg less ( &lt; ) 95.0 kg body mass index ( BMI ) 18.5 29.9 kilogram per square meter ( kg/m^2 ) Able communicate well Investigator , understand protocol requirement restriction , willing comply requirement entire trial Nonsmoker ( = 0 cigarette , pipe , cigar ) least 3 month prior start trial Electrocardiogram ( ECG ) recording ( 12lead ) without sign clinically relevant pathology , particular QTcB &lt; 450 millisecond ( m ) Vital sign ( systolic blood pressure , diastolic blood pressure pulse ) supine position within normal range show clinically relevant deviation judge Investigator Any surgical medical condition , include finding medical history prestudy assessment , significant disease , opinion Investigator , constitute risk contraindication participation subject trial could interfere trial objective , conduct evaluation History gastrointestinal ( GI ) tract surgery , GI tract diseases acute GI tract infection within last 2 week could influence GI absorption and/or motility accord Investigator 's opinion Any clinically relevant abnormality safety laboratory parameter judge Investigator Positive result serology examination Hepatitis B surface antigen ( HBsAg ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) Have ascertain presumptive contraindication hypersensitivity active drug substance and/or formulation ' ingredient Have clinically significant history allergic condition Investigator considers may affect outcome trial History presence drug abuse alcohol abuse ( define assessment investigator ) screen admission Blood donation loss 400 mL blood within 3 month first administration investigational product Administration investigational product use investigational device within 60 day prior first dosing may affect pharmacokinetics investigational product Subjects use drug may affect pharmacokinetics ( PK ) PZQ 15 day first administration investigational product last PK sample Consumption substances know potent inhibitor inducer cytochrome P450s ( CYPs ) within 2 week first administration investigational product Unlikely comply protocol requirement , instruction trialrelated restriction Nonacceptance study breakfast Excessive consumption beverage contain xanthine ( great [ &gt; ] 5 cup coffee day equivalent ) inability refrain use caffeinecontaining beverage 48 hour first administration investigational product discharge clinic Subject Investigator SubInvestigator , research assistant , pharmacist , trial coordinator , staff relative thereof directly involve conduct trial Vulnerable subject Legal incapacity limit legal capacity</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ODT-PZQ</keyword>
	<keyword>Bio-availability</keyword>
	<keyword>Praziquantel</keyword>
	<keyword>Cysticide</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>